Development of an HIV Rev-dependent dual-reporter cell for anti-HIV drug screenin
$70,745R03FY2012AINIH
George Mason University, Fairfax VA
Investigators
Linked publications, trials & patents
Abstract
DESCRIPTION (provided by applicant): HIV/AIDS is a worldwide pandemic afflicting 40 million people, and currently there is no cure. The proposed research is to develop a new reporter cell line to facilitate the discovery of novel anti-HIV drugs. This prospective reporter cell system will employ a Rev-dependent lentiviral vector, which has been shown previously to be highly specific to HIV infection. This novel system will greatly facilitate the development of a novel cell- based drug screening platform. Additionally, by employing two reporters this system can be used in multiple assay formats and would be amenable to high-throughput screens for antiretroviral compounds.
View original record on NIH RePORTER →